1:36 PM
 | 
May 12, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Proteon ups Phase III PATENCY-2 enrollment

Proteon Therapeutics Inc. (NASDAQ:PRTO) will for the second time increase enrollment in the ongoing Phase III PATENCY-2 trial of vonapanitase to treat chronic kidney disease (CKD) to correct a calculation error in the trial’s statistical plan. The trial will now enroll 600 CKD patients undergoing surgery for arteriovenous fistula (AVF) creation, up from 500 previously. Proteon said the error had overstated the trial’s power to evaluate...

Read the full 310 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >